ADMAR

Quthero Accepted into Prestigious MaRS-adMare Tx Accelerator

Retrieved on: 
Thursday, December 14, 2023
Corporation, Accelerator, Heart, Senior, Therapy, Scar, Regeneration, Patient, Ecosystem, Partnership, ADMAR, Corporate development, Red, Growth, Doctor of Philosophy, Dermatology, Environment, Pharmaceutical industry, MaRS Discovery District

TORONTO, Dec. 14, 2023 /PRNewswire/ -- Quthero, a biotech company with a unique, patented Q-peptide platform technology was accepted into the MaRS – adMare Therapeutics (Tx) Accelerator which provides a distinctive ecosystem for the development of novel therapeutics in Ontario and Canada.

Key Points: 
  • TORONTO, Dec. 14, 2023 /PRNewswire/ -- Quthero, a biotech company with a unique, patented Q-peptide platform technology was accepted into the MaRS – adMare Therapeutics (Tx) Accelerator which provides a distinctive ecosystem for the development of novel therapeutics in Ontario and Canada.
  • "The partnership between MaRS and adMare presents Quthero with a unique opportunity to access the most experienced players in the development of new therapeutics.
  • MaRS and adMare joined their expertise and resources to support the growth of therapeutics ventures in the MaRS-adMare Accelerator.
  • "MaRS and adMare are excited to support Quthero and their team, in the first cohort of the Therapeutics (Tx) Accelerator, to bring their great science to the market and ultimately to patients.

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

Retrieved on: 
Tuesday, October 10, 2023
ADMAR, Cystic Fibrosis Foundation, MBA, Doctor of Philosophy, Research, Pregnancy specific biological substances, G.H. Raisoni Department of Microbiology and Biotechnology, Bristol Myers Squibb, Berkeley, MD, Master of Science, Organization, Therapy, Liver, Genetics, University, Mutation, Rachel Haurwitz, Disease, University of Miami Division of Surgical Neurooncology, Arrowhead Pharmaceuticals, Leonard M. Miller School of Medicine, Cystic fibrosis, Annual Review of Cancer Biology, University of Virginia Cancer Center, Acute leukemia, DSM-IV codes, Gene editing, Astex Pharmaceuticals, Specific, Dasatinib, CNS, Patient, Vaccine, Pharmaceutical industry, Investment, Microbiology, Immunology

Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.

Key Points: 
  • Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.
  • TORONTO, Oct. 10, 2023 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Steven Kanner, PhD, as an Independent Director.
  • The appointment coincides with renewed investment from Lumira Ventures and adMare BioInnovations to advance the preclinical development of therapeutics based on Specific's proprietary Dualase® platform gene editors.
  • The additional investment from Lumira Ventures and adMare BioInnovations will be used to advance preclinical testing of Dualase gene editors in liver, ocular and CNS disorders.

Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer

Retrieved on: 
Thursday, April 20, 2023
Oncology, Health, Radiology, Research, Science, Pharmaceutical, Biotechnology, PK, Carcinoma, Drug development, Doctor of Philosophy, Investment, Radionuclide, Venture round, Beta, Food, Therapeutic index, ADMAR, Viking Global Investors, Cancer, Bone marrow, Record, Radiochemistry, Radiopharmaceutical, Antibody, Terra Venture Partners, SCLC, AbCellera, DLL3, Protein, Patient, Kidney, Neoplasm, FDA, Therapy, IND, Regulation of tobacco by the U.S. Food and Drug Administration, FC, Radio, Isotope, Medical imaging, Management

Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today announced it has raised $142 million in combined Series A and B financing.

Key Points: 
  • Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today announced it has raised $142 million in combined Series A and B financing.
  • “Abdera’s ROVEr™ platform enables the design of antibody-based radiopharmaceuticals that are ideally suited to specific cancer targets with optimized PK properties to pair with a radioisotope of choice and maximize therapeutic impact.
  • “DLL3 is a well-validated target for SCLC, a cancer with few treatment options,” said Yvonne Yamanaka, Ph.D., principal, venBio Partners.
  • “We are pleased to have worked with the company’s talented co-founders to grow Abdera and we look forward to what this team can achieve.

adMare BioInnovations Launches the adMare Tx Accelerator to Support Growth of Promising Early-stage Therapeutics Ventures across Canada

Retrieved on: 
Monday, January 30, 2023
The Honourable, Ecosystem, ICC, IP, Economic development, DNA, Knowledge, Executive Committee, Government, Workforce Innovation in Regional Economic Development, Incubator, Ministry, Pandemic, Old Courts Commercial Complex, Hisar, Therapy, ADMAR, Institut Français de la Mode, Research, Pharmaceutical industry, Management, Metropolis, MaRS Discovery District, Innovation, Science

Based on the success of this program, adMare is launching a national Tx Accelerator to support Canada's most promising and innovative early-stage therapeutics ventures with the potential for significant market impact.

Key Points: 
  • Based on the success of this program, adMare is launching a national Tx Accelerator to support Canada's most promising and innovative early-stage therapeutics ventures with the potential for significant market impact.
  • Therapeutic ventures are invited to submit their application by March 1st to be part of the first Tx Accelerator cohort.
  • We are proud to welcome ventures across Canada to our Accelerator," stated Gordon C. McCauley, President and CEO of adMare BioInnovations.
  • "The adMare Tx Accelerator program supports companies in the life sciences and health technologies in various stages of development and commercialization.

Inversago Pharma Raises $95 million CAD in Series C Financing

Retrieved on: 
Monday, October 17, 2022
Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Kidney disease, Metabolic syndrome, Amgen, IND, ADMAR, T2D, IPF, T1D, General partnership, Socially responsible investing, IPO, Patient, United Nations Principles of Medical Ethics, Diabetes, FTQ, Hypertriglyceridemia, Diabetic nephropathy, Investment, EUR, New Enterprise Associates, Technology, HTG, NASH, CB1, Initial public offering, Company, Doctor of Philosophy, Health, DKD, Obesity, NEA, BGV, Fatty liver disease, Series, Progressive, Idiopathic pulmonary fibrosis, FDA, Solution, Leadership, Financial services, Pharmaceutical industry, Fine chemical

Inversago Pharma Inc. (Inversago), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C funding of $95 million CAD (approximately $70 million USD), led by New Enterprise Associates (NEA).

Key Points: 
  • Inversago Pharma Inc. (Inversago), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C funding of $95 million CAD (approximately $70 million USD), led by New Enterprise Associates (NEA).
  • Proceeds from the Series C financing will be used to move Inversagos lead program, INV-202, into a Phase 2 clinical trial in Diabetic Kidney Disease in Q4 2022.
  • We are privileged to have the support and commitment of such an impressive investor syndicate at this critical stage of the Companys development, said Franois Ravenelle, PhD, Chief Executive Officer of Inversago Pharma.
  • Todays financing reflects our shared vision and collaboration with the Companys management as they initiate a Phase 2 clinical trial with INV-202.

SATT[1] Conectus and Find Therapeutics Sign Licensing Agreement to Develop a Promising New Therapy for Multiple Sclerosis and other demyelinating diseases

Retrieved on: 
Tuesday, June 7, 2022
People, Multiple Sclerosis Society, Eye, IMS, Program, Research, THE, Institute, Multiple sclerosis, Degenerative disease, Central nervous system, Nerve Damage, Laboratory, AND, Inflammation, CEO, Neuron, Neuroprotection, Disease, Regeneration, Investment, Optic neuritis, Therapy, Patient, MS, ADMAR, Multiple Sclerosis Society of Canada, Immune system, Remyelination, Autoimmune disease, Quality of life, Technology transfer, Inserm, Industry, Drug design, University of Strasbourg, Element, Find, Pharmaceutical industry, Medical device

Promising preclinical data show that this innovative therapy, by overcoming the molecular barriers of myelin regeneration, could restore myelin function.

Key Points: 
  • Promising preclinical data show that this innovative therapy, by overcoming the molecular barriers of myelin regeneration, could restore myelin function.
  • According to the Multiple Sclerosis Society of Canada, Canada has one of the highest MS rates in the world with 1 in every 400 people affected.
  • Initial preclinical pharmacology studies, funded by SATT Conectus, have demonstrated very encouraging results, delivering increased myelin and better function after treatment.
  • Find Therapeutics, is dedicated to the development of next generation trans-membrane allosteric modulators to treat rare and inflammatory diseases.

Government of Canada advances domestic life sciences sector by supporting Canadian companies, talent, and research and development

Retrieved on: 
Wednesday, March 30, 2022
Pandemic, Government of Canada, Investment, Growth, Enrique Dussel, Research, Epidemic, Government, SME, ADMAR, Health, McGill Executive Institute, Safety, COVID-19, The Honourable, R, Pharmacy, Renewable energy, Pharmaceutical industry, Management, Creative industries, Animal, Industry, Science, BC

With the guidance of Canada's Biomanufacturing and Life Sciences Strategy ,the government is actively supporting the growth of a strong, competitive domestic life sciences sector, with cutting-edge biomanufacturing capabilities.

Key Points: 
  • With the guidance of Canada's Biomanufacturing and Life Sciences Strategy ,the government is actively supporting the growth of a strong, competitive domestic life sciences sector, with cutting-edge biomanufacturing capabilities.
  • It is through Canadian talent and businesses that we will solve our world's toughest problems and make Canada a hub for life sciences and biomanufacturing."
  • Budget 2021 provides a total of $2.2 billion over seven years toward growing a vibrant domestic life sciences sector and securing pandemic preparedness.
  • This budget funding provides foundational investments to help build Canada's talent pipeline and research systems as well as to foster the growth of Canadian life sciences firms.

Research breakthrough shows promise for new therapeutics to help reduce sugar and fat and maintain good health as we age

Retrieved on: 
Tuesday, January 11, 2022
Research, Glycerol, Human, CSO, Respiration (physiology), Glucose, Ageing, CEO, Canadian Institutes of Health Research, Oxidative stress, Obesity, Animal, Therapy, Multimedia, ADMAR, Type 2 diabetes, Nature Communications, Public, University, Medical device, Pharmaceutical industry

MONTREAL, Jan. 11, 2022 /PRNewswire/ - New research published in Nature Communications suggests that a newly-identified enzyme could reduce sugar and fat in the body and help us live longer healthier lives.

Key Points: 
  • MONTREAL, Jan. 11, 2022 /PRNewswire/ - New research published in Nature Communications suggests that a newly-identified enzyme could reduce sugar and fat in the body and help us live longer healthier lives.
  • This research was supported by a grant from the Canadian Institutes of Health Research.
  • NIMIUM Therapeutics is a Montreal biotech focused on the development of an innovative therapeutic to treat cardiometabolic diseases.
  • The research is based on G3PP, an enzyme found to play a central role in glucose, lipid, and energy metabolism.

Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations

Retrieved on: 
Thursday, December 16, 2021
Organization, Western University, Schulich School of Medicine & Dentistry, Ecosystem, Genomics, Cell, Intelligence, Genome, Gene editing, Growth, Industry, Biotron (Western University), Medicine, Lists of diseases, Bachelor of Engineering, CEO, Research, Gene, Robotics, Patient, Therapy, St John's Innovation Centre, DNA, Efficiency, Multimedia, ADMAR, Partnership, Vaccine, Pharmaceutical industry, Medical device, Pregnancy specific biological substances, Investment, Specific

TORONTO, Dec. 16, 2021 /PRNewswire/ - Specific Biologics Inc. ("Specific") today announced that it has closed its first institutional financing, led by Lumira Ventures and adMare BioInnovations which have recently established an innovative partnership to build Canadian life sciences companies.

Key Points: 
  • TORONTO, Dec. 16, 2021 /PRNewswire/ - Specific Biologics Inc. ("Specific") today announced that it has closed its first institutional financing, led by Lumira Ventures and adMare BioInnovations which have recently established an innovative partnership to build Canadian life sciences companies.
  • "We are excited to work alongside adMare and the Specific team to grow the company and bring transformative therapies to patients."
  • "The investment in Specific Biologics stems from a new partnership between adMare and Lumira Ventures," commented Dr. Frdric Lematre Auger, Managing Partner, Investments with adMare.
  • Specific Biologics Inc. ("Specific") is a venture-backed early-stage biotechnology company on a mission to develop novel gene editing technologies to treat diseases through precision gene editing.

BIOVECTRA Announces Appointment of Steven M. Klosk and Gordon C. Mccauley to Board

Retrieved on: 
Thursday, October 21, 2021
Health, Manufacturing, Other Science, Other Manufacturing, Science, Pharmaceutical, Biotechnology, JD, Compliance, Research, Permira, CDMO, Creativity, Industry, ADMAR, MBA, Patient, CGMP, Cambrex Corporation, Leadership, Time, CEO, Health, Sale, Heart, Management, Fine chemical

BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex Corporation, to its board of directors.

Key Points: 
  • BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex Corporation, to its board of directors.
  • Mr. Klosk and Mr. McCauley are innovative executives who offer a wealth of experience to the BIOVECTRA Board of Directors, says Oliver Technow, CEO of BIOVECTRA.
  • Gordon McCauley BA, MBA, ICD.D is an accomplished life science executive and investor, having served as president and senior executive of several health care enterprises.
  • I am excited to help as a director with BIOVECTRA, says Gordon McCauley.